1. Home
  2. TLPH vs PYPD Comparison

TLPH vs PYPD Comparison

Compare TLPH & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Talphera Inc.

TLPH

Talphera Inc.

HOLD

Current Price

$1.23

Market Cap

70.3M

Sector

Health Care

ML Signal

HOLD

Logo PolyPid Ltd.

PYPD

PolyPid Ltd.

HOLD

Current Price

$5.12

Market Cap

71.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLPH
PYPD
Founded
2005
2008
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
70.3M
71.7M
IPO Year
2010
2014

Fundamental Metrics

Financial Performance
Metric
TLPH
PYPD
Price
$1.23
$5.12
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$12.25
AVG Volume (30 Days)
300.6K
158.9K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,151,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$3.06
52 Week High
$1.57
$5.73

Technical Indicators

Market Signals
Indicator
TLPH
PYPD
Relative Strength Index (RSI) 47.07 59.30
Support Level $1.22 $4.15
Resistance Level $1.29 $5.67
Average True Range (ATR) 0.08 0.22
MACD -0.01 0.05
Stochastic Oscillator 30.77 81.43

Price Performance

Historical Comparison
TLPH
PYPD

About TLPH Talphera Inc.

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

About PYPD PolyPid Ltd.

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Share on Social Networks: